Incyte announced that data from the Novartis Phase 2 GEOMETRY mono-1 study demonstrating that treatment with Tabrecta resulted in positive overall response rates for some patients with metastatic non-small cell lung cancer.
Results have been published in The New England Journal of Medicine.
“The GEOMETRY mono-1 study results published in The New England Journal of Medicine further highlight the clinical benefit that Tabrecta can provide to patients with metastatic METex14 NSCLC,” said Steven Stein, M.D., chief medical officer, Incyte. “Having a therapy that targets a recognized oncogenic driver offers a much-needed treatment option for patients living with this aggressive form of lung cancer and we are proud that the world-class discovery program at Incyte contributed to the fulfillment of this unmet medical need.”
Non small-cell lung cancer accounts for approximately 85 percent of lung cancer diagnoses.
Novartis has exclusive worldwide development and commercialization rights to Tabrecta. Incyte is eligible for a total of over $500 million in milestones as well as royalties of between 12-14 percent on global net sales by Novartis.
Tabrecta was licensed to Novartis in 2009.
Incyte has seen seen strong growth with its blood cancer drug Jakafi and is working to build a drug pipeline. If Tabrecta proves to be a blockbuster drug, licensing fees would allow more funds for the pipeline.
